{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T04:34:29Z","timestamp":1795149269370,"version":"4.10.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-66590-2","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:55:37Z","timestamp":1764172537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study"],"prefix":"10.1038","volume":"16","author":[{"given":"Andreas","family":"Papagiannis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Majjaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5429-7888","authenticated-orcid":false,"given":"Francois P.","family":"Duhoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-7511","authenticated-orcid":false,"given":"Elisa","family":"Agostinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Stanciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4806-0370","authenticated-orcid":false,"given":"Thila","family":"Vanhulst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-0819","authenticated-orcid":false,"given":"Laurence","family":"Buisseret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Larsimont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Veys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Paesmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana Besse","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7412-9163","authenticated-orcid":false,"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieveke","family":"Ameye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5044-0747","authenticated-orcid":false,"given":"Francesc","family":"Madriles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Cash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1110-3801","authenticated-orcid":false,"given":"Roberto","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1150-1295","authenticated-orcid":false,"given":"Karen","family":"Willard-Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5745-9977","authenticated-orcid":false,"given":"Christos","family":"Sotiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vuylsteke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1434-9460","authenticated-orcid":false,"given":"Patrick","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4493-3748","authenticated-orcid":false,"given":"Michail","family":"Ignatiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"66590_CR1","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrclinonc.2013.124","volume":"10","author":"M Ignatiadis","year":"2013","unstructured":"Ignatiadis, M. & Sotiriou, C. Luminal breast cancer: from biology to treatment. Nat. Rev. Clin. Oncol. 10, 494\u2013506 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"66590_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2023","unstructured":"Morrison, L., Loibl, S. & Turner, N. C. The CDK4\/6 inhibitor revolution \u2014 a game-changing era for breast cancer treatment. Nat. Rev. Clin. Oncol. 21, 89\u2013105 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"66590_CR3","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston, S. R. D. et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE). J. Clin. Oncol. 38, 3987\u20133998 (2020).","journal-title":"J. Clin. Oncol."},{"key":"66590_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon, D. et al. Ribociclib plus endocrine therapy in early breast cancer. N. Engl. J. Med. 390, 1080\u20131091 (2024).","journal-title":"N. Engl. J. Med."},{"key":"66590_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","volume":"22","author":"EL Mayer","year":"2021","unstructured":"Mayer, E. L. et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 22, 212\u2013222 (2021).","journal-title":"Lancet Oncol."},{"key":"66590_CR6","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1200\/JCO.20.03639","volume":"39","author":"S Loibl","year":"2021","unstructured":"Loibl, S. et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer \u2014 the PENELOPE-B trial. J. Clin. Oncol. 39, 1518\u20131530 (2021).","journal-title":"J. Clin. Oncol."},{"key":"66590_CR7","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1093\/annonc\/mdy456","volume":"29","author":"M Brand\u00e3o","year":"2018","unstructured":"Brand\u00e3o, M. & Ignatiadis, M. CDK4\/6 inhibitors as neoadjuvant treatment in breast cancer \u2014 what can we learn? Ann. Oncol. 29, 2274\u20132278 (2018).","journal-title":"Ann. Oncol."},{"key":"66590_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel, S. et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature 548, 471\u2013475 (2017).","journal-title":"Nature"},{"key":"66590_CR9","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","volume":"26","author":"SA Hurvitz","year":"2020","unstructured":"Hurvitz, S. A. et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR+\/HER2\u2212 breast cancer. Clin. Cancer Res. 26, 566\u2013580 (2020).","journal-title":"Clin. Cancer Res."},{"key":"66590_CR10","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s43018-021-00215-7","volume":"2","author":"JI Griffiths","year":"2021","unstructured":"Griffiths, J. I. et al. Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4\/6 therapy. Nat. Cancer 2, 658\u2013671 (2021).","journal-title":"Nat. Cancer"},{"key":"66590_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56279-x","volume":"16","author":"JI Griffiths","year":"2025","unstructured":"Griffiths, J. I. et al. Cellular interactions within the immune microenvironment underpin resistance to cell cycle inhibition in breast cancers. Nat. Commun. 16, 2132 (2025).","journal-title":"Nat. Commun."},{"key":"66590_CR12","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","volume":"23","author":"CX Ma","year":"2017","unstructured":"Ma, C. X. et al. NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor\u2013positive breast cancer. Clin. Cancer Res. 23, 4055\u20134065 (2017).","journal-title":"Clin. Cancer Res."},{"key":"66590_CR13","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1158\/1078-0432.CCR-19-4191","volume":"27","author":"C De Angelis","year":"2021","unstructured":"De Angelis, C. et al. Activation of the IFN signaling pathway is associated with resistance to CDK4\/6 inhibitors and immune checkpoint activation in ER-positive breast cancer. Clin. Cancer Res. 27, 4870\u20134882 (2021).","journal-title":"Clin. Cancer Res."},{"key":"66590_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00625-7","volume":"10","author":"T Pascual","year":"2024","unstructured":"Pascual, T. et al. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy. NPJ Breast Cancer 10, 25 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"66590_CR15","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/2159-8290.CD-20-1540","volume":"11","author":"M Heckler","year":"2021","unstructured":"Heckler, M. et al. Inhibition of CDK4\/6 promotes CD8 T-cell memory formation. Cancer Discov. 11, 2564\u20132581 (2021).","journal-title":"Cancer Discov."},{"key":"66590_CR16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1158\/2326-6066.CIR-20-0401","volume":"9","author":"EJ Lelliott","year":"2021","unstructured":"Lelliott, E. J. et al. Combined BRAF, MEK, and CDK4\/6 inhibition depletes intratumoral immune-potentiating myeloid populations in melanoma. Cancer Immunol. Res. 9, 136\u2013146 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"66590_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","volume":"8","author":"J Deng","year":"2018","unstructured":"Deng, J. et al. CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 8, 216\u2013233 (2018).","journal-title":"Cancer Discov."},{"key":"66590_CR18","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","volume":"24","author":"P Savas","year":"2018","unstructured":"Savas, P. et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 24, 986\u2013993 (2018).","journal-title":"Nat. Med."},{"key":"66590_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ccell.2023.01.004","volume":"41","author":"B Virassamy","year":"2023","unstructured":"Virassamy, B. et al. Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. Cancer Cell 41, 585\u2013601 (2023).","journal-title":"Cancer Cell"},{"key":"66590_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev-immunol-101320-020220","volume":"42","author":"SN Christo","year":"2024","unstructured":"Christo, S. N., Park, S. L., Mueller, S. N. & Mackay, L. K. The multifaceted role of tissue-resident memory T cells. Annu. Rev. Immunol. 42, 317\u2013345 (2024).","journal-title":"Annu. Rev. Immunol."},{"key":"66590_CR21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1126\/science.1163612","volume":"323","author":"E Teixeiro","year":"2009","unstructured":"Teixeiro, E. et al. Different T cell receptor signals determine CD8+ memory versus effector development. Science 323, 502\u2013505 (2009).","journal-title":"Science"},{"key":"66590_CR22","doi-asserted-by":"publisher","first-page":"eabc1495","DOI":"10.1126\/science.abc1495","volume":"375","author":"A Fassl","year":"2022","unstructured":"Fassl, A., Geng, Y. & Sicinski, P. CDK4 and CDK6 kinases: from basic science to cancer therapy. Science 375, eabc1495 (2022).","journal-title":"Science"},{"key":"66590_CR23","doi-asserted-by":"publisher","first-page":"pky005","DOI":"10.1093\/jncics\/pky005","volume":"2","author":"Q Gao","year":"2018","unstructured":"Gao, Q. et al. Major impact of sampling methodology on gene expression in estrogen receptor-positive breast cancer. JNCI Cancer Spectr. 2, pky005 (2018).","journal-title":"JNCI Cancer Spectr."},{"key":"66590_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0696-2","volume":"18","author":"E L\u00f3pez-Knowles","year":"2016","unstructured":"L\u00f3pez-Knowles, E. et al. Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas. Breast Cancer Res. 18, 39 (2016).","journal-title":"Breast Cancer Res."},{"key":"66590_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s43018-020-00135-y","volume":"2","author":"AC Watt","year":"2021","unstructured":"Watt, A. C. et al. CDK4\/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nat. Cancer 2, 34\u201348 (2021).","journal-title":"Nat. Cancer"},{"key":"66590_CR26","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.3390\/cancers14164000","volume":"14","author":"H Saghir","year":"2022","unstructured":"Saghir, H. et al. How reliable are gene expression-based and immunohistochemical biomarkers assessed on a core-needle biopsy? A study of paired core-needle biopsies and surgical specimens in early breast cancer. Cancers 14, 4000 (2022).","journal-title":"Cancers"},{"key":"66590_CR27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/jso.26780","volume":"125","author":"JA Crozier","year":"2022","unstructured":"Crozier, J. A. et al. High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancer. J. Surg. Oncol. 125, 596\u2013602 (2022).","journal-title":"J. Surg. Oncol."},{"key":"66590_CR28","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/modpathol.2017.43","volume":"30","author":"L Buisseret","year":"2017","unstructured":"Buisseret, L. et al. Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. Mod. Pathol. 30, 1204\u20131212 (2017).","journal-title":"Mod. Pathol."},{"key":"66590_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4048\/jbc.2017.20.3.297","volume":"20","author":"K You","year":"2017","unstructured":"You, K. et al. Comparison of core needle biopsy and surgical specimens in determining intrinsic biological subtypes of breast cancer with immunohistochemistry. J. Breast Cancer 20, 297\u2013303 (2017).","journal-title":"J. Breast Cancer"},{"key":"66590_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00404-021-05996-x","volume":"304","author":"M P\u00f6lcher","year":"2021","unstructured":"P\u00f6lcher, M. et al. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer. Arch. Gynecol. Obstet. 304, 783\u2013790 (2021).","journal-title":"Arch. Gynecol. Obstet."},{"key":"66590_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19, 40\u201350 (2018).","journal-title":"Lancet Oncol."},{"key":"66590_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller, A. B., Hoogstraten, B., Staquet, M. & Winkler, A. Reporting results of cancer treatment. Cancer 47, 207\u2013214 (1981).","journal-title":"Cancer"},{"key":"66590_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann. Oncol. 26, 259\u2013271 (2015).","journal-title":"Ann. Oncol."},{"key":"66590_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"66590_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05072-0","volume":"9","author":"T Duhen","year":"2018","unstructured":"Duhen, T. et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat. Commun. 9, 2724 (2018).","journal-title":"Nat. Commun."},{"key":"66590_CR36","doi-asserted-by":"publisher","first-page":"673042","DOI":"10.3389\/fmolb.2021.673042","volume":"8","author":"A Boisson","year":"2021","unstructured":"Boisson, A. et al. Fluorescent multiplex immunohistochemistry coupled with other state-of-the-art techniques to systematically characterize the tumor immune microenvironment. Front. Mol. Biosci. 8, 673042 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"66590_CR37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/biostatistics\/kxj036","volume":"8","author":"KK Dobbin","year":"2007","unstructured":"Dobbin, K. K. & Simon, R. M. Sample size planning for developing classifiers using high-dimensional DNA microarray data. Biostatistics 8, 101\u2013117 (2007).","journal-title":"Biostatistics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66590-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66590-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66590-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T14:02:53Z","timestamp":1767103373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66590-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["66590"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66590-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MI reports consultancy roles for Seattle Genetics, Daichi, AstraZeneca, Menarini\/Stemline, Gilead Sciences, and Novartis (all unrelated to the present work), Rejuveron Senescence Therapeutics, grant\/research support (to institution) from Roche, Inivata Inc, and Natera Inc (all unrelated to the present work), Pfizer, and uncompensated roles for EORTC (EORTC Board of Directors 2018\u20132021, Chair EORTC Breast Cancer Group 2021\u20132025). FPD reports grants from Fondation Belge Contre le Cancer, institutional payments from Roche, Pfizer, AstraZeneca, Eli Lilly, Novartis, Amgen, Daiichi Sankyo, Pierre-Fabre, Gilead, Seagen, and MSD, and support for attending meetings from Amgen, Roche, Teva, Pfizer, Daiichi Sankyo, AstraZeneca, Gilead, and MSD (all unrelated to the present work). ORCID ID: 0000-0002-5429-7888.L.B. reports Research funding to my Institution from Astra Zeneca\/MedImmune Advisory role for Domain Therapeutics, iTeos Therapeutics, AstraZeneca Salary partly covered by the Fondation contre le Cancer (Belgium) Member of the IMMUcan Consortium (EORTC) Travel grants from GILEAD, AstraZeneca, Roche (all unrelated to the present work).E.A. reports Research grant to my institution: Gilead Advisory Board for AstraZeneca Receipt of honoraria or consultation fees: Eli Lilly, AstraZeneca, Abscint, Bayer Travel\/meeting grants: Eli Lilly, AstraZeneca, Daiichi Sankyo, Abscint, Menarini, Gilead (all unrelated to the present work).ORCID ID: 0000-0003-0295-7511. A.A. reports Advisory role: Amgen, AstraZeneca, Bayer, Daiichi, EISAI, Genomic Health, Hengrui, Innate, Ipsen, Leo Pharma, Lilly, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Menarini Speaker fees: Amgen, AstraZeneca, Bayer, Daiichi, EISAI, Genomic Health, Ipsen, Leo Pharma, Lilly, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Hikma, Sothema. Research grants to the Institute: BMS, Roche (all unrelated to the present work). R.S. reports Advisory Board role for BMS, Roche, Exact Sciences, Daicchii Sankyo, Astra Zeneca, Case45. Research funding by Roche, Puma, Merck, BMS and Travel and congress-registration support by Roche, Merck, Astra Zeneca (all unrelated to the present work).F.M. and T.P.C. are employes of Rejuversen. The remaining authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11659"}}